Skip to main content
Assets
Amgen logo
AMGN.NASDAQ
Amgen
Health Care · Biotechnology

Biotechnology pioneer discovering, developing, manufacturing, and delivering human therapeutics for serious illnesses.

HQ: United StatesListed: United States

Historical AI Forecasts

Audit every published iPulse AI forecast batch and immutable historical research document for Amgen.

Historical AI Forecasts

Amgen Inc. (AMGN.NASDAQ) AI FORECASTS & ADVISOR ANALYSIS

Read and compare the 12 individual AI Advisor deep-dive reports, including their forecast paths, ratings, price targets, and reasoning.

Updated on 28 November 2025Deep analysis 28 November 2025

PublisherRusslan Ramdowar
25 min readAudit All Past Forecasts

AI Advisor 1 AI

Independent Investor FrameworkAI Researcher

Model rating

Buy

5-Year Return Est.

+57.2%

Includes 1.80% annual net dividend contribution

1. Investment Thesis — Base Case

The most reasonable thesis projects Amgen effectively navigating its transition period. MariTide will likely succeed in clinical trials, securing approval by late 2027, though it may share the market rather than dominate it, serving as a robust growth pillar alongside a stabilized Horizon portfolio. The for Prolia and Xgeva will create revenue headwinds in 2026-2027, but Amgen's proven ability to manage lifecycle extensions and its own aggressive biosimilar revenue growth (e.g., Amjevita, Wezlana) will mitigate the impact. The company will maintain its shareholder-friendly , growing the dividend while . The stock offers a balanced risk-reward profile, steadily compounding as the obesity pipeline de-risks.

Historical prices and published forecast

Historical prices and published forecastObserved prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.171.35259.74348.13436.53524.92Nov 2020May 2023Nov 2025May 2028Nov 2030Forecast starts
  • Observed price
  • Published advisor forecast
Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.
View chart values
Historical prices and published forecast — published chart values
SeriesDateValue (USD)
Observed price2020-11-23221
Observed price2020-12-14230
Observed price2020-12-23222
Observed price2021-01-18250
Observed price2021-01-22255
Observed price2021-02-17232
Observed price2021-03-02224
Observed price2021-03-20248
Observed price2021-03-24247
Observed price2021-04-19258
Observed price2021-04-23257
Observed price2021-04-28240
Observed price2021-05-24244
Observed price2021-06-01236
Observed price2021-06-23241
Observed price2021-07-02249
Observed price2021-07-23245
Observed price2021-08-18225
Observed price2021-08-23224
Observed price2021-09-09215
Observed price2021-09-22215
Observed price2021-10-18207
Observed price2021-11-04214
Observed price2021-11-17205
Observed price2021-11-30201
Observed price2021-12-18222
Observed price2021-12-22222
Observed price2022-01-17231
Observed price2022-02-08235
Observed price2022-02-16222
Observed price2022-02-21221
Observed price2022-03-19235
Observed price2022-03-23237
Observed price2022-04-18255
Observed price2022-04-22254
Observed price2022-05-01234
Observed price2022-05-27255
Observed price2022-06-13237
Observed price2022-06-22242
Observed price2022-07-09248
Observed price2022-08-04247
Observed price2022-08-17252
Observed price2022-08-22247
Observed price2022-09-17228
Observed price2022-09-21227
Observed price2022-10-13249
Observed price2022-10-21255
Observed price2022-11-16287
Observed price2022-11-21287
Observed price2022-12-17268
Observed price2022-12-30261
Observed price2023-01-07274
Observed price2023-01-20262
Observed price2023-02-15240
Observed price2023-02-20239
Observed price2023-03-09226
Observed price2023-03-22230
Observed price2023-04-13251
Observed price2023-04-21243
Observed price2023-05-17225
Observed price2023-05-26218
Observed price2023-06-16230
Observed price2023-06-29222
Observed price2023-07-17230
Observed price2023-07-30233
Observed price2023-08-16263
Observed price2023-09-02255
Observed price2023-09-15261
Observed price2023-10-03266
Observed price2023-10-11285
Observed price2023-10-20278
Observed price2023-10-29264
Observed price2023-11-19265
Observed price2023-12-15275
Observed price2023-12-20276
Observed price2024-01-10307
Observed price2024-02-01317
Observed price2024-02-14289
Observed price2024-02-18284
Observed price2024-03-15272
Observed price2024-03-28283
Observed price2024-04-15265
Observed price2024-04-19266
Observed price2024-05-15317
Observed price2024-05-19311
Observed price2024-05-28301
Observed price2024-06-19308
Observed price2024-07-15332
Observed price2024-07-23335
Observed price2024-08-10323
Observed price2024-09-05325
Observed price2024-09-13333
Observed price2024-09-22335
Observed price2024-09-26319
Observed price2024-10-18321
Observed price2024-11-13291
Observed price2024-11-22291
Observed price2024-12-13271
Observed price2025-01-04259
Observed price2025-01-13266
Observed price2025-01-17271
Observed price2025-02-08297
Observed price2025-02-16294
Observed price2025-03-10325
Observed price2025-03-19318
Observed price2025-04-09284
Observed price2025-05-01288
Observed price2025-05-14271
Observed price2025-05-18272
Observed price2025-06-13295
Observed price2025-06-22274
Observed price2025-07-09300
Observed price2025-07-22309
Observed price2025-08-09288
Observed price2025-08-22294
Observed price2025-09-12276
Observed price2025-09-25273
Observed price2025-10-04297
Observed price2025-10-26292
Observed price2025-11-12338
Observed price2025-11-29345
Observed price2025-12-12321
Observed price2025-12-25332
Observed price2026-01-03323
Observed price2026-01-16331
Observed price2026-02-07372
Observed price2026-02-20380
Observed price2026-03-13371
Observed price2026-03-18355
Observed price2026-04-04346
Observed price2026-04-21349
Observed price2026-05-09330
Observed price2026-05-17329
Observed price2026-06-12345
Observed price2026-06-17342
Observed price2026-07-04370
Observed price2026-07-17366
Observed price2026-08-12417
Observed price2026-09-02444
Observed price2026-09-14382
Observed price2026-09-15376
Observed price2026-09-18386
Published advisor forecast2025-11-26345
Published advisor forecast2026-05-27358
Published advisor forecast2026-11-27372
Published advisor forecast2027-05-27389
Published advisor forecast2027-11-27405
Published advisor forecast2028-05-27422
Published advisor forecast2028-11-27439
Published advisor forecast2029-05-27454
Published advisor forecast2029-11-27468
Published advisor forecast2030-05-27482
Published advisor forecast2030-11-27495

2. Scenarios & Signals

Bull case

The bull case hinges on the transformational success of MariTide (AMG 133) in the obesity and metabolic disease market. In this scenario, Phase 3 'MARITIME' trials demonstrate best-in-class efficacy with a durable weight loss profile and superior monthly or quarterly dosing convenience compared to daily/weekly competitors. This propels Amgen to capture a significant double-digit share of the projected $100B+ obesity market by 2030. Simultaneously, the integration of Horizon Therapeutics exceeds synergy targets, with Tepezza returning to high-growth trajectory globally. Amgen's own biosimilar portfolio aggressively captures share from competitors like Stelara, offsetting the Prolia/Xgeva . The market re-rates AMGN from a value pharma to a high-growth biotech multiple, driving the stock significantly higher.

Bear case

The bear case envisions a failure or significant safety signal in the MariTide Phase 3 program, shattering the premium currently baked into the stock price. Without this growth engine, investor focus shifts aggressively to the '' facing Prolia and Xgeva, where biosimilar erosion accelerates faster than anticipated starting in 2026, severely impacting high-margin revenue. The Horizon Therapeutics acquisition proves burdensome, with Tepezza sales plateauing due to competitive thyroid eye disease therapies. Burdened by debt from the acquisition and lacking a near-term blockbuster replacement, Amgen faces and multiple contraction, reverting to a low-growth valuation.

Complete advisor preview locked

Unlock this report and every AI Advisor

Sign in to check your access, or upgrade to the Base plan to read this report and open every advisor.

Sign in to check accessView Base planReturn to latest AI Consensus